HCA Healthcare (HCA) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues rose 10.3% year-over-year to $17.492 billion, driven by higher admissions, improved efficiencies, and revenue per equivalent admission.

• Net income increased to $1.461 billion ($5.53 per diluted share), up from $1.193 billion ($4.29) in Q2 2023, with adjusted diluted EPS up 28% to $5.50.

• Adjusted EBITDA for Q2 2024 was $3.55 billion, up 16% year-over-year.

• Inpatient admissions grew 5.8%, emergency room visits rose 5.5%, and payer mix improved, with commercial volumes at 36.2% of equivalent admissions.

• Strategic investments in people, facilities, and technology are expected to sustain positive outcomes and support continued demand growth.

Financial highlights

• Same facility revenue grew 10% year-over-year, supported by higher acuity and improved payer mix.

• Operating margin improved to 12.8% in Q2 2024 from 11.4% in Q2 2023, with labor costs as a percent of revenue down 200 basis points.

• Cash flow from operations was $1.971 billion in Q2 2024, down $504 million year-over-year due to higher tax payments and Medicaid program timing.

• Capital expenditures were $1.281 billion in Q2 2024, and share repurchases totaled $1.367 billion.

• Six-month 2024 revenues totaled $34.831 billion, with net income of $3.052 billion.

Outlook and guidance

• 2024 revenue guidance raised to $69.75–$71.75 billion, net income to $5.675–$5.975 billion, Adjusted EBITDA to $13.75–$14.25 billion, and diluted EPS to $21.60–$22.80.

• Share repurchases for 2024 are estimated at $6 billion, with capital spending expected between $5.1–$5.3 billion.

• Management believes liquidity is sufficient for foreseeable needs, supported by cash flows, credit facilities, and market access.

• Volume growth for the year is anticipated in the 4–6% range, with continued moderation in professional fee expense growth.